Coronavirus Vaccine Stocks: Challenges With Manufacturing, Distribution, And the Cold Chain

Fool.com's Healthcare and Cannabis Bureau Chief Corinne Cardina interviewed Richard Horton on Motley Fool Live on Oct. 9. Horton runs the British medical journal The Lancet and has been at the forefront of publishing data about the coronavirus pandemic this year. He also recently published a book called The COVID-19 Catastrophe.

Here, Horton explains what investors should know about manufacturing, distribution, and the "cold chain" when it comes to mRNA vaccine candidates like those being developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), as well as by Moderna (NASDAQ: MRNA).

Continue reading

Source Fool.com